ERBB2 and neuroendocrine carcinoma: Thus, we speculated that HER2-based chemotherapy may eliminate HER2-positive adenocarcinoma components; aggressive NEC components without HER2 positivity, which are resistant to HER2-based chemotherapy, became conspicuous [17].